A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
Blood (2021) 138 (Supplement 1): 96.
Currently there are no citedby results. Try again later.
